Immunoglobulin G4-Related Bilateral Palpebral Conjunctival Involvement

J Craniofac Surg. 2023 Oct 1;34(7):e626-e628. doi: 10.1097/SCS.0000000000009426. Epub 2023 May 29.

Abstract

The authors show a case with immunoglobulin G4 (IgG4)-related bilateral palpebral conjunctival mass and reviewed 7 similar previously reported cases. Our case was a 42-year-old woman who presented with a 2-year history of a left palpebral conjunctival mass. Pathologic examination of the specimens harvested from the mass revealed marked IgG4-positive plasma cell infiltration. The serum IgG4 level was within the normal limit. Although the mass was completely excised, the lesion recurred 1 month after the surgery, and another new lesion developed in the right upper palpebral conjunctiva. The patient was given 30 mg of oral prednisolone daily, which was tapered gradually. At a 10-month follow-up, the patient continued to take 15 mg of oral prednisolone. The lesions subsided on both sides. On the basis of the literature review, normal serum IgG4 level and upper eyelid lesions may be features of IgG4-related bilateral palpebral conjunctival lesions, and systemic steroids may be effective for this entity.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Conjunctiva* / pathology
  • Eyelids
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoglobulin G
  • Prednisolone* / therapeutic use

Substances

  • Prednisolone
  • Glucocorticoids
  • Immunoglobulin G